A PHASE I, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF BLYG8824A ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT IN PATENTS WITH LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER
2019-004874-24CANCER COLORRECTAL AVANZADOFundación Jiménez DíazInvestigador: MORENO GARCIA VICTOR